Q3 2026 Peptide News

The third quarter of 2026 brought notable momentum to peptide drug development, marked by an influx of oral peptide drug approvals, novel inhaled peptide delivery models, exciting advances in personalized cancer vaccines, and a welcome shift of attention toward women's health.

Together, these updates highlight key clinical, regulatory, and technological developments across the peptide space from Q3 2026.

Metabolic Health & Endocrinology

Eli Lilly announced successful results from two additional Phase 3 clinical trials evaluating retatrutide, its investigational GLP-1/GIP/glucagon triple receptor agonist. The data positions retatrutide for upcoming global regulatory submissions in chronic weight management and related comorbidities.

The U.S. FDA approved Merck’s Lipfendra (enlicitide), marking a historic milestone as the first and only once-daily oral PCSK9 inhibitor to reduce LDL-C in adults with hypercholesterolemia.

Ascletis Pharma has dosed the first participants in a U.S. Phase 1 clinical trial evaluating ASC36, an orally bioavailable amylin receptor agonist peptide designed for chronic weight management. The program adds further momentum to non-injectable metabolic peptides entering early-phase clinical development.

MannKind Corporation and Rose Pharma entered into a licensing and collaboration agreement to develop a rapid-acting, short-duration inhaled GLP-1 formulation for mealtime weight management using MannKind’s Technosphere dry-powder inhalation platform.

Hanmi Pharm has entered into an exclusive licensing agreement with Genentech for the global development, manufacturing, and commercialization of HM17321, a novel UCN2 analog peptide for obesity. This first-in-class treatment is designed to simultaneously drive weight loss and preserve lean body mass, with Genentech slated to take over its manufacturing and clinical advancement following the completion of Phase 1 trials.

Oncology & Precision Conjugates

ITM Radiopharma reported primary results from its Phase 3 COMPETE trial in The Lancet, comparing the targeted radiolabeled somatostatin analog ¹⁷⁷Lu-edotreotide (ITM-11) directly against standard-of-care everolimus in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The trial indicated that ITM-11 showed improved progression free survival relative to the current standard of care.

In the Phase 1 FOCUS-01 study, Avacta demonstrated clinical proof of mechanism for AVA6103, a Fibroblast Activation Protein (FAP)-targeted peptide-drug conjugate (PDC) incorporating an exatecan warhead. The platform releases the payload selectively within the tumor microenvironment while sparing healthy tissue.

Treos Bio presented translational findings showing that its multi-peptide immunotherapy PolyPEPI1018, when administered with anti-PD-L1 therapy, actively remodels the immunosuppressive tumor microenvironment in microsatellite-stable (MSS) metastatic colorectal cancer.

At ESMO Congress 2026, Evaxion Biotech presented three-year clinical follow-up data for EVX-01, an AI-designed personalized neoantigen peptide vaccine evaluated in patients with metastatic melanoma. These extended findings build on earlier data demonstrating long-lasting treatment responses.

Viferaxs raised $12 million to expand its oncology pipeline and advance its lead therapeutic peptide candidate, CLLTAXS01, through Phase 2 clinical trials for patients with chronic lymphocytic leukemia (CLL).

Rare Diseases, Hematology & Specialty Modalities

Takeda and Protagonist Therapeutics received FDA approval for Mimrylo (rusfertide), a synthetic, injectable cyclic peptide that mimics the master iron-regulating hormone hepcidin. The approval offers a novel therapeutic alternative to repeated therapeutic phlebotomies in polycythemia vera.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Zealand Pharma’s Zeydovio (glepaglutide), a long-acting synthetic GLP-2 analog administered via autoinjector for short bowel syndrome.

NEJM Evidence published Phase 3 trial data evaluating BioMarin’s Voxzogo (vosoritide), a C-type natriuretic peptide (CNP) analog, in children with hypochondroplasia, confirming sustained increases in annualized growth velocity.

At ESPE 2026, Ascendis Pharma shared the first clinical data from infants treated with TransCon CNP (navepegritide), a long-acting CNP prodrug designed for once-weekly dosing to treat children with achondroplasia. The results demonstrated strong safety and encouraging clinical responses.

Hemab Therapeutics dosed the first subject in its Phase 1 trial evaluating HMB-003, an investigational fatty acid–conjugated peptide engineered to control severe heavy menstrual bleeding.

Danish biotech Teitur Trophics announced positive safety and biomarker outcomes from a first-in-human Phase 1 clinical trial of its circular peptide candidate, demonstrating blood-brain barrier penetration and neuroprotective activity in Parkinson's disease models.

Immunology, Respiratory & Drug Delivery Technologies

Johnson & Johnson received European Commission marketing authorization for Icotyde (icotrokinra), the first oral targeted peptide approved as a first-line systemic therapy for adults and adolescents with moderate-to-severe plaque psoriasis. Originally discovered with Protagonist Therapeutics, icotrokinra selectively inhibits the IL-23 receptor.

A randomized clinical study published in Nature Communications confirmed the safety and pharmacokinetics of escalating doses of inhaled LTI-03, an anti-fibrotic peptide delivering targeted therapy directly to lung tissue for idiopathic pulmonary fibrosis (IPF).

Researchers published a new delivery framework in ScienceDirect demonstrating how tunable gelatin microparticles provide sustained, non-degrading release kinetics for fragile therapeutic peptides, addressing systemic enzymatic breakdown.

Acquisitions and Regulatory Guidance

Samsung Biologics announced an all cash offer to acquire CDMO PolyPeptide Group, a move incentivized by strong growth in metabolic therapeutics. The acquisition will significantly expand Samsung Biologics' global manufacturing capacity.

Cordon acquired AmbioPharm, expanding its peptide production capabilities and geographic presence.

Bachem announced a strategic collaboration to build a new large-scale peptide production facility in Sisslerfeld, Switzerland. Driven by sustained high demand for peptide APIs, this greenfield project involves long-term supply commitments and is scheduled to begin commercial production in 2030.

The FDA published 17 revised draft Product Specific Guidances to streamline the development and approval of generic peptide therapeutics, including Ozempic, Wegovy, and Mounjaro. The modernized framework updates evaluation standards across five key scientific areas and withdraws 2021 guidance to accelerate market competition and lower drug costs.